Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
23/10/2026-01:12 23/10/2026-03:20 מחשבים וטכנולוגיה Ars Technica דיווח
Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, feeds.issuerdirect.com
